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Abstract
Background: Genetic markers for thyroid cancers identified by microarray analysis have offered limited predictive accuracy
so far because of the few classes of thyroid lesions usually taken into account. To improve diagnostic relevance, we have
simultaneously analyzed microarray data from six public datasets covering a total of 347 thyroid tissue samples representing
12 histological classes of follicular lesions and normal thyroid tissue. Our own dataset, containing about half the thyroid
tissue samples, included all categories of thyroid lesions.
Methodology/Principal Findings: Classifier predictions were strongly affected by similarities between classes and by the
number of classes in the training sets. In each dataset, sample prediction was improved by separating the samples into
three groups according to class similarities. The cross-validation of differential genes revealed four clusters with functional
enrichments. The analysis of six of these genes (APOD, APOE, CLGN, CRABP1, SDHA and TIMP1) in 49 new samples showed
consistent gene and protein profiles with the class similarities observed. Focusing on four subclasses of follicular tumor, we
explored the diagnostic potential of 12 selected markers (CASP10, CDH16, CLGN, CRABP1, HMGB2, ALPL2, ADAMTS2,
CABIN1, ALDH1A3, USP13, NR2F2, KRTHB5) by real-time quantitative RT-PCR on 32 other new samples. The gene expression
profiles of follicular tumors were examined with reference to the mutational status of the Pax8-PPARc, TSHR, GNAS and
NRAS genes.
Conclusion/Significance: We show that diagnostic tools defined on the basis of microarray data are more relevant when a
large number of samples and tissue classes are used. Taking into account the relationships between the thyroid tumor
pathologies, together with the main biological functions and pathways involved, improved the diagnostic accuracy of the
samples. Our approach was particularly relevant for the classification of microfollicular adenomas.
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Introduction
Over the past few years, the use of microarray technologies has
contributed to the identification of new markers for the diagnosis
and prognosis of human tumors. Cancer research usually involves
the study of a single class of tumor and the corresponding normal
tissue. Increasing the number of binary studies does not necessarily
improve the relevance of the molecular signature. Thus, a meta-
analysis comparing 40 types of cancer in various tissues relative to
their normal counterpart allowed the identification of a common
signature essential to carcinogenesis but may fail to distinguish
between different classes of tumor affecting a given organ, which
may therefore have specific prognoses [1]. Moreover, the same
signature may also appear in a variety of other cellular contexts
such as inflammatory processes.
Thyroid nodules are extremely common in the adult popula-
tion, but less than 20% of the nodules are malignant [2]. Papillary
thyroid carcinoma (PTC), diagnosed on the basis of characteristic
nuclear features, is the most frequent malignant thyroid tumor.
According to the 2004 WHO report, the diagnosis of minimal
invasive follicular thyroid carcinoma (FTC) is problematic because
of its morphological and molecular similarities to benign follicular
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features render the differential diagnosis of follicular tumors
difficult on histologic examination and call for new molecular or
biological markers [4,5]. To date, microarray analyses of thyroid
tumors have essentially compared two classes of tissue [6–11].
These studies have either searched for specific markers by
comparing a particular class of thyroid tumor to the corresponding
normal tissue, or looked for markers of malignancy by examining
the most frequent benign and malignant classes of thyroid tumor
(usually the FTA and PTC classes). The predictive accuracy of the
markers identified is therefore rather limited with regard to tumors
belonging to other classes. For example, the CITED1 gene, which
was claimed to be a significant marker distinguishing PTC from
normal tissue [9] turned out to be less specific when data from
FTC samples were included [8]. Furthermore, this gene did not
even figure among the 42 best PTC marker genes detected by a
meta-analysis that included benign tumors [12]. Meta-analyses
may increase not only the number of classes required to define
more relevant markers but also increase the imbalance in the
representation of some classes. In a recent analysis, cross-validated
marker genes from 21 studies differentiated benign from malignant
thyroid tissues [13]. However, the majority of these were pertinent
to the diagnosis of PTC since these thyroid cancers accounted for
more than 40% of the samples studied. This highlights the bias
due to the recruitment of thyroid samples for microarray studies
and the consequent failure in identifying classifiers for clinical
applications despite the large number of analyses exploited.
Few studies have simultaneously compared more than four
types of thyroid tissue [5,14–17]. In one of these [15], we were
able to refine the diagnosis of tumors of uncertain malignancy by
the simultaneous analysis of eight types of thyroid tissue. These
promising results encouraged further research on relevant markers
of thyroid tumors, taking into account more classes and subclasses
of interest, as some authors have recommended [18]. In the
present study, we have explored gene-expression signatures from
the majority of the differentiated follicular pathologies of thyroid
tissue. We have used published data or data available from the
Gene Expression Omnibus (GEO) of the U. S. National Center for
Biotechnology Information, as well as specifically generated data,
to simultaneously analyze several datasets containing information
on various pathologies, including datasets with many histological
subclasses. Our analysis, covering the major subtypes of thyroid
tissue, may be expected to enhance microarray data concerning
thyroid tumors and lead to the definition of more reliable tissue-
specific markers for thyroid lesions.
Results
We have simultaneously analyzed 347 thyroid tissue samples
from six datasets (Table 1). The Fontaine dataset, generated by
our own laboratory [15], comprised 166 thyroid tissue samples, i.e.
about half the total number of samples.
Molecular classification of thyroid pathologies
To analyze the global classification of the follicular thyroid
lesions in the Fontaine dataset, we defined the centroid of each
class of tissue by a composite signature of mean gene-expression
levels. The hierarchical clustering of the class centroids (Figure 1A)
revealed three groups. The first group comprised benign thyroid
lesions and normal tissues (green boxes for FTA, MNG, WT, AT,
and GD); the second contained malignant lesions (red boxes for
FTC, TUM and PTC); and the third included oncocytic tumors
and microfollicular adenomas (blue boxes for FTAb, OTUM,
OTA and OTC). These groups, supported by a high robustness
index of 0.938 and a discrepancy index of 0.337, are respectively
referred to as the ‘benign’, ‘malignant’ and ‘oncocytic’ groups. The
three groups, cross-validated in the Giordano dataset (Figure 1C),
presented almost perfect robustness (=1) and discrepancy indices
Table 1. Datasets, classes and samples.
Datasets Fontaine et al. 2008 Giordano et al.2006 Weber et al.2005 Jarzab et al. 2005 He et al. 2005 Reyes et al. 2006
Microarray platform Single channel
cDNA microarrays
Affymetrix
GeneChip
HG U133A
Affymetrix
GeneChip
HG U133A
Affymetrix
GeneChip
HG U133A
Affymetrix
GeneChip HG
U133 Plus 2.0
Affymetrix
GeneChip HG
U133 Plus 2.0
(Probes) (9,216) (22,283) (22,283) (22,283) (54,681) (54,681)
Tissue samples Symbol 166 93 24 32 18 14
Wild Type tissue WT 24 4 - 16 9 7
Autoimmune Thyroiditis AT 5 - - - - -
Grave’s Disease GD 5 - - - - -
Follicular Thyroid Adenoma FTA 26 10 12 - - -
Microfollicular Thyroid Adenoma FTAb 17 - - - - -
Multi Nodular Goitre MNG 24 - - - - -
Follicular Thyroid Carcinoma FTC 3 - 6 - - -
FTC with PAX8/PPARc fusion FTC+ -7 - - - -
FTC without PAX8/PPARc fusion FTC- - 6 - - - -
Oncocytic Thyroid Adenoma OTA 30 7 - - - -
Oncocytic Thyroid Carcinoma OTC 4 8 6 - - -
Oncocytic Tumour of Uncertain OTUM 5 - - - - -
Malignancy
Papillary Thyroid Carcinoma PTC 13 51 - 16 9 7
Tumour of Uncertain Malignancy TUM 10 - - - - -
doi:10.1371/journal.pone.0007632.t001
Micrarray and Thyroid Lesions
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(OTA, OTC, correlation .0.6) and a group of malignant tumors
(PTC, FTC+). The third group, predominantly composed of
benign tumors and normal tissues (WT, FTA), also included the
FTC- group.
We computed the prediction accuracy for the benign, malignant
and oncocytic groups of thyroid tissue classes as defined above.
The signature of each group was trained versus all the other
samples, and its accuracy was compared with the predictive
accuracy of individual lesions (Table 2). In both datasets, the
positive accuracy for each group was greater than the best
accuracy reported for an individual lesion within the group. The
high proportion of PTC (79%) in the malignant group from the
Giordano dataset may explain the good accuracy for this group
despite the rate of discrepancy shown in the Figure 1C. The
separation of the samples into three groups on the basis of class
similarities led to improved sample prediction in the two datasets.
The matrix of 66 pairwise correlation coefficients between the
classes (Figure 1B) allowed a detailed observation of the similarities
and dissimilarities in the Fontaine dataset. All the classes in the
benign/normal group were positively correlated with each other.
Some pairs of classes were highly correlated (correlation coefficient
.0.4), e.g. FTA with MNG, and AT with GD. All the classes in
Figure 1. Molecular classification of thyroid tissues. The centroid signatures of the thyroid tissues were compared to each other in the
Fontaine dataset generated by our laboratory [15], and compared to the Giordano dataset [5]. Centroids were defined as the mean gene-expression
signature of each tissue class over all the genes. Panel A shows the hierarchical clustering of the tissues in the Fontaine dataset. The dendrogram can
be cut into three robust branches (black circles) defining three groups of classes. The groups contain benign lesions and normal tissue (green boxes),
malignant tumors (red boxes), or oncocytic tumors and microfollicular adenomas (blue boxes). Panel B shows pairwise correlation coefficients
between the tissue classes from the Fontaine dataset. The heatmap represents a symmetrical matrix of color-coded correlation coefficients. Tissue
classes are ordered as in the hierarchical clustering and marked with the same three colors (green, red and blue). Panel C shows the hierarchical
clustering of the tissues in the Giordano dataset. The dendrogram can be cut into three robust branches (black circles) defining three groups of
classes. The groups contain heterogeneous lesions and normal tissue (green boxes), malignant tumors (red boxes), or oncocytic tumors (blue boxes).
The two datasets show three groups containing similar tissue classes. WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA: macrofollicular
thyroid adenoma; FTAb: microfollicular thyroid adenoma; GMN, multinodular goiter; FTC: follicular thyroid carcinoma (FTC+: with Pax8/PPARc
translocation; FTC-: without Pax8/PPARc translocation); OTA: oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; TUM: tumor of uncertain
malignancy; OTUM: oncocytic tumor of uncertain malignancy; GD: Grave’s disease; and AT: autoimmune thyroı ¨ditis.
doi:10.1371/journal.pone.0007632.g001
Table 2. Prediction of samples by considering three groups
of tissue classes. Values can be compared to the range of
accuracies for individual lesions that composed each group.
Fontaine dataset Giordano dataset
Group
Individual
lesions Group
Individual
lesions
Benign group 0,79 0.11–0.71 0,76 0.31–0.47
Malignant group 0,69 0.24–0.67 0,93 0.93–0.94
Oncocytic group 0,75 0.02–0.64 0,86 0.52–0.62
doi:10.1371/journal.pone.0007632.t002
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The TUM class had a stronger correlation with PTC than with
FTC (respectively 0.354 and 0.274). This similarity between TUM
and PTC has previously been demonstrated within this dataset
and with independent samples [15]. In the oncocytic group, the
classes of oncocytic tumors were positively correlated with each
other, except for the FTAb class. Finally, we were able to identify
220 non-redundant genes for the molecular classification of each
of the 11 subcategories of follicular thyroid pathologies explored
(Table 3).
Class prediction from binary and from complete training
We compared classifiers defined from many classes, i.e. the
entire dataset (complete training), and two classes, i.e. one
pathological class versus normal thyroid tissue (binary training).
The predictive accuracy for the samples of a class, i.e. the positive
accuracy, was always higher after binary training than after
complete training in the two main datasets (Figure 2A). With
regard to complete training, only two classes in each dataset had
similar performances: PTC and AT in the Fontaine dataset, FTC+
and PTC in the Giordano dataset.
The classifiers defined by complete training in the Fontaine
dataset were evaluated in five other thyroid datasets (Table 4).
With respect to the positive accuracy computed from intra-dataset
cross-validations, the PTC, FTC, FTA and OTC classifiers turned
out to be more accurate than expected. The OTA classifier was
less accurate than expected, with a value of 0.59 versus 0.64, but
only one other dataset contained this class of thyroid tissue.
Functional analysis of cross-validated differential genes
In the two largest datasets containing the main kinds of thyroid
lesions [5,15], we searched for cross-validated differential genes.
The two lists of differential genes had an intersection of 104 genes
that separated five gene clusters from the hierarchical clustering of
classes shared by the two datasets (Figure 3 and Table 5). The
functions and pathways identified were mainly related to oncocytic
and papillary tumors (Clusters 1, 3 and 4). Gene ontologies were
associated with oxido-reductive mechanisms (Cluster 1, 28 genes),
nitrogen metabolism and cell communication (Cluster 3, 17 genes),
glucocorticoid receptor signaling and leukocyte extravasation
(Cluster 4, 24 genes). A cluster of genes showed a specific profile
for tumors of malignant potential, for which the transcriptional
factors involved in the primary anabolic and catabolic cell
pathways were down-regulated (Cluster 2, 25 genes). However
in Cluster 2, the heterogeneous profiles of some classes (FTA) were
suspected of containing molecular subgroups whereas the profiles
for WT were almost homogeneous. A cluster of 10 genes (Cluster
5) was not clearly specific to the tissue classes as their profiles
differed between the two datasets. In the Fontaine dataset, 52% of
the cross-validated genes belonged to at least two of the 11 classes
of lesion (data not shown).
Independent validation of selected genes by real-time
RT-PCR
To test the relevance of some markers selected by cross-
validation between the two main datasets, we measured the
expression levels of six differential genes, CASP10, CDH16,
CLGN, CRABP1, HMGB2 and ALPL2, on 32 new follicular
tumor samples, including eight samples each of FTA, FTAb, OTA
and FTC (Figure 4A). For all six genes, the expression levels
differentiated between follicular adenomas (macro- and micro-
follicular) and follicular carcinomas (t-test, p,0.05). In all cases
except one (CASP10, F-test, p,0.05), the gene expression level
differentiated not only between macro- and micro-follicular
adenomas but also between follicular adenomas and oncocytic
adenomas, as in the case of CDH16 and CRABP1 genes.
To test the relevance of our microarray analysis in identifying
subclasses of adenomas, we measured the expression levels of six
differential genes from the microfollicular adenoma subclass
(ADAMTS2, CABIN1, ALDH13, USP13, NR2F2 and
KRTHB5), on the same 32 follicular thyroid samples mentioned
above (Figure 4B). Except for NR2F2 (p,0.954), all genes were
differentially expressed not only between the three subclasses of
adenomas (t-test, p,0.05), but also between the four groups of
follicular tumors (F-tests, p,0.05 for ADAMTS2, CABIN1,
ALDH13, USP13; p=0.06 for KRTHB5).
Mutational status of follicular tumors
The mutational status of three genes (TSHR, GNAS and
NRAS) was investigated on 59 solitary follicular adenomas (43
from the microarray study, and 16 from the RT-PCR study) to
compare these to the expression profile of FTA samples and
evaluate their functional status. To identify the role of the PAX8-
PPARG translocation in the expression profile of the FTC class,
the rearrangement status for PAX8-PPARG was explored on 11
FTC samples (three samples from the microarray study, and eight
samples from the RT-PCR study).
In the follicular adenoma samples, we identified mutations in
the TSHR gene in seven of the 59 samples (12%): six of which
were macrofollicular adenomas from the microarray study and
one was a macrofollicular adenoma from the RT-PCR study. All
the mutations were situated in the seventh transmembrane domain
of the TSH receptor (from codon 619 to codon 633). Our results
are in accordance with the mutational status of the TSH receptor
gene described in the literature, especially concerning the
macrofollicular subtype [19]. One macrofollicular adenoma
presented a mutation in codon 201 of the GNAS gene. None of
the microfollicular adenomas showed TSHR and GNAS muta-
tions in the four exons explored. Five microfollicular adenomas
(four from the microarray study, and one from the RT-PCR study)
were positive for the NRAS mutation in codon 61.
No PAX8-PPARG translocation was found in any of the FTC
samples studied.
Protein expression of selected differential genes in
independent samples
We collected 49 new tissue samples to measure the protein
expression of six selected differential genes in the classes common
to the two main datasets (FTA, FTC, OTA, OTC, PTC and WT),
and also for the AT class as a non-tumoral control (Figure 5).
There was significant differential expression between the classes
(F-tests, p,0.05) for five proteins (SDHA, CLGN, APOD,
CRABP1 and TIMP1). The APOE protein was not differentially
expressed (p,0.932). Among the differentially expressed proteins,
three had profiles similar to their gene profiles (SDHA, APOD and
TIMP1), whereas two proteins (CLGN and CRABP1) showed
some differences, as reported in previous studies of selected classes
[20,21]. The expression of the CLGN protein was higher in the
FTA and FTC samples, but not in the oncocytic samples, contrary
to the gene profile observed. The CRABP1 protein was
differentially expressed between the FTA samples compared to
the PTC and FTC samples, with a decreased expression of both
RNA and protein in the malignant tumors. Considering the
appurtenance of this gene to Cluster 2 (Figure 3), the expression of
CRABP1 protein could serve to distinguish between the benign
and malignant groups of thyroid tissue.
Micrarray and Thyroid Lesions
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Symbol Clone ID Class
Cross validation
support (%)
Parametric
p-value t-value
Fold-
change
ABCB9 36371 AT 100 1,00E-07 6,81 3,28
SEP-02 729542 AT 100 2,67E-01 21,11 0,75
SEP-05 448163 AT 100 1,00E-07 7,03 4,96
AAAS 740617 AT 99 3,00E-07 5,36 3,34
ABCA3 52740 AT 97 4,99E-01 0,68 1,13
ABCA8 284828 AT 97 1,86E-01 21,33 0,74
ABCB1 1837488 AT 97 2,26E-01 21,22 0,72
ABCB8 238705 AT 97 3,51E-01 20,94 0,84
ABCC3 208097 AT 96 1,54E-01 1,43 1,64
ABCF2 1086914 AT 96 1,00E-07 6,91 3,37
BATF 1929371 AT 83 1,00E-07 10,52 6,03
C18orf51 742649 AT 62 1,00E-07 9,87 7,47
CARD11 665651 AT 46 1,00E-07 10,85 4,72
CBFA2T2 43629 AT 39 1,00E-07 10,18 10,03
CD38 1352408 AT 29 1,00E-07 10,18 7,22
CD79A 1056782 AT 25 1,00E-07 11,14 8,58
CD79B 155717 AT 25 1,00E-07 11,91 10,51
CXCL6 2108870 AT 14 1,00E-07 10,13 4,29
EPPB9 668454 AT 7 1,00E-07 9,67 9,03
DKFZp667B0210 1844689 AT 3 1,00E-07 9,30 4,83
PLXNB2 1420676 FTA 65 6,00E-07 5,21 1,70
TBC1D17 739955 FTA 62 4,00E-07 5,27 1,56
ZNF76 745003 FTA 59 8,00E-07 5,15 1,51
KIAA1196 738938 FTA 52 1,40E-06 5,01 1,52
ASGR1 25883 FTA 48 1,25E-05 4,51 1,75
BCL2L11 300194 FTA 42 6,00E-06 4,68 1,42
DAP 725371 FTA 41 6,20E-06 4,67 1,51
CABIN1 1844968 FTA 40 1,12E-05 4,53 1,59
FLJ14981 24532 FTA 31 1,84E-04 3,83 1,50
RAD51L1 295412 FTA 30 4,23E-05 4,21 1,66
TSPAN1 376003 FTA 26 3,52E-05 4,25 1,57
IMAGE:745465 745465 FTA 25 2,58E-02 2,25 1,24
PLCG1 1174287 FTA 25 8,36E-05 24,04 0,67
COL18A1 359202 FTA 24 3,20E-05 4,28 1,60
RPS6KA2 22711 FTA 23 3,77E-05 4,24 1,57
CaMKIINalpha 173820 FTA 22 9,52E-04 3,37 1,35
KLF1 208991 FTA 16 3,01E-03 3,01 1,49
BAT3 24392 FTA 13 8,11E-04 3,41 1,42
PDK4 487379 FTA 11 1,00E-02 22,61 0,70
IMAGE:24065 24065 FTA 6 4,52E-04 23,58 0,75
KRTHB5 364569 FTAb 86 1,00E-07 6,02 1,94
METRN 487475 FTAb 86 1,00E-07 5,68 2,15
DCI 667892 FTAb 74 6,00E-07 5,19 1,63
IFI30 740931 FTAb 68 4,90E-06 24,73 0,41
ALCAM 172828 FTAb 64 1,21E-05 24,51 0,68
ADAMTS2 364844 FTAb 55 1,61E-04 3,86 1,41
ETF1 146976 FTAb 54 1,12E-04 3,96 1,54
TP53I11 667514 FTAb 44 1,22E-04 3,94 1,94
IMAGE:487086 487086 FTAb 42 1,52E-04 23,88 0,67
Micrarray and Thyroid Lesions
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support (%)
Parametric
p-value t-value
Fold-
change
IMAGE:666315 666315 FTAb 35 5,63E-04 3,52 1,52
GRB10 564994 FTAb 33 1,80E-04 3,83 1,42
ISG20 740604 FTAb 33 3,51E-05 24,26 0,60
SPARC 267358 FTAb 33 1,09E-04 3,97 1,47
HAS3 667533 FTAb 28 1,07E-04 3,97 1,52
USP13 666007 FTAb 20 9,96E-05 3,99 1,56
KRT4 1173570 FTAb 13 2,87E-04 3,71 1,65
LHFP 591534 FTAb 9 2,24E-03 23,11 0,74
PCDHB15 730593 FTAb 9 1,06E-03 23,33 0,74
TPM2 740620 FTAb 9 9,35E-03 2,63 1,45
DKFZp434M202 743118 FTAb 2 5,77E-03 22,80 0,76
C22orf9 667250 FTC 89 2,00E-07 25,43 0,34
SUCLG2 687551 FTC 83 7,00E-07 25,18 0,27
LAPTM4A 726684 FTC 77 4,00E-07 25,26 0,24
KIAA1576 743426 FTC 76 1,00E-07 5,70 3,33
NR2F2 72744 FTC 65 2,60E-06 4,87 3,11
CHST3 665327 FTC 62 2,90E-06 24,85 0,32
PAI-RBP1 236055 FTC 55 5,30E-06 24,71 0,29
IMAGE:729896 729896 FTC 54 3,00E-07 5,34 3,22
ZBTB16 2467442 FTC 52 4,72E-05 4,18 4,68
ZNF364 471834 FTC 52 5,80E-06 24,69 0,39
GHITM 25077 FTC 50 5,30E-06 24,71 0,31
LRP8 415554 FTC 49 1,43E-04 3,90 2,74
CEECAM1 666784 FTC 45 2,67E-04 3,73 2,22
HIST1H4C 682451 FTC 43 1,57E-05 24,45 0,25
TIE1 743043 FTC 35 5,46E-05 4,14 2,52
SH3RF2 744797 FTC 22 5,37E-03 2,82 2,18
MGC5395 238840 FTC 15 5,07E-04 3,55 2,66
EMX2 365121 FTC 14 6,95E-03 22,73 0,51
LRRC28 26519 FTC 13 1,51E-03 23,23 0,40
GFRA3 2716748 FTC 11 4,52E-03 2,88 1,93
TTC19 136366 GD 72 1,57E-04 3,87 1,87
ATP6V1G2 726424 GD 61 1,91E-04 3,82 2,22
IMAGE:23817 23817 GD 61 3,65E-04 23,64 0,52
IMAGE:178161 178161 GD 52 6,99E-04 3,46 2,53
BDKRB2 665674 GD 50 6,16E-03 2,78 2,15
IMAGE:744385 744385 GD 48 1,37E-02 2,49 1,70
LOC150837 258698 GD 47 5,84E-04 3,51 1,81
SSX1 262894 GD 47 5,97E-04 3,50 1,76
DHX57 24623 GD 46 1,69E-03 23,19 0,59
RAI14 731711 GD 46 8,19E-03 2,68 1,56
IMAGE:180851 180851 GD 45 5,36E-03 22,82 0,61
MGC5566 53119 GD 43 1,74E-03 3,18 1,85
D21S2056E 740140 GD 36 2,44E-03 3,08 1,72
IMAGE:729489 729489 GD 31 1,28E-03 3,28 2,95
KIAA1737 122063 GD 29 1,78E-03 3,18 1,67
MLH3 250771 GD 21 8,59E-03 2,66 1,59
IMAGE:53081 53081 GD 18 3,35E-03 2,98 1,77
TERF1 135773 GD 16 2,81E-02 2,22 1,45
Table 3. Cont.
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DCXR 724596 GD 15 3,39E-03 22,97 0,61
IMAGE:136686 136686 GD 15 6,29E-02 1,87 1,48
FLJ11127 668625 MNG 88 2,30E-06 4,90 1,54
RODH 471641 MNG 83 1,51E-05 4,46 2,57
MGC17299 713422 MNG 59 6,54E-05 4,10 1,37
NR2F2 72744 MNG 57 3,10E-04 3,69 1,40
ZNF83 486356 MNG 50 3,72E-04 3,64 1,32
IMAGE:744505 744505 MNG 43 2,51E-04 3,74 1,38
IMAGE:745187 745187 MNG 42 1,15E-03 23,31 0,78
CAV1 309645 MNG 41 3,38E-04 3,66 1,59
CNTN6 257773 MNG 41 2,34E-04 3,76 1,38
C10orf116 740941 MNG 40 2,82E-04 3,71 1,72
CALM1 594510 MNG 39 1,21E-03 23,30 0,77
IMAGE:726782 726782 MNG 39 3,97E-04 3,62 1,38
IMAGE:250463 250463 MNG 28 6,76E-03 2,74 1,29
IMAGE:731726 731726 MNG 28 3,90E-04 3,62 1,52
TTC17 665668 MNG 28 5,24E-04 3,54 1,31
PRKCA 768246 MNG 25 9,12E-04 23,38 0,71
NR4A1 1073288 MNG 19 1,88E-03 23,16 0,64
PDLIM1 135689 MNG 14 9,76E-04 3,36 1,48
IMAGE:731292 731292 MNG 11 2,65E-02 22,24 0,68
SLC17A2 207920 MNG 9 2,70E-02 22,23 0,67
MLL 80688 OTA 76 1,00E-07 28,18 0,55
ALDH1A3 486189 OTA 67 1,00E-07 6,38 1,79
CLECSF12 258865 OTA 63 1,00E-07 7,66 3,51
IMAGE:485104 485104 OTA 60 1,00E-07 7,32 2,25
DCN 666410 OTA 49 1,00E-07 27,19 0,50
PROZ 430471 OTA 47 1,00E-07 7,05 2,76
CHRDL2 485872 OTA 46 1,00E-07 6,72 1,58
B3GNTL1 53341 OTA 39 9,00E-07 5,10 2,04
SNRP70 729971 OTA 39 1,00E-07 27,00 0,52
HSPC159 365045 OTA 38 1,00E-07 6,86 1,70
C4A 724366 OTA 32 1,00E-07 26,30 0,39
SLC6A8 725877 OTA 31 1,00E-07 27,00 0,23
OBSCN 730926 OTA 29 1,00E-07 6,95 1,55
IMAGE:731616 731616 OTA 27 1,00E-07 6,88 2,42
DC12 724895 OTA 24 1,00E-07 6,67 1,71
UBA52 530069 OTA 16 4,40E-06 24,75 0,29
KCNQ2 179534 OTA 14 1,00E-07 6,43 1,77
HCNGP 365934 OTA 11 1,92E-05 4,40 1,40
C9orf72 726849 OTA 10 4,40E-06 24,75 0,69
GNAI1 753215 OTA 6 8,90E-06 4,59 1,48
SDHA 40304 OTC 95 1,00E-07 6,29 3,16
DNALI1 782688 OTC 72 1,00E-07 25,53 0,24
IMAGE:382423 382423 OTC 50 1,50E-06 5,00 3,52
ATP11C 667991 OTC 47 2,30E-05 4,36 2,17
C1QBP 173371 OTC 46 2,70E-06 4,86 2,47
DCN 666410 OTC 43 6,80E-06 24,65 0,29
MT1F 78353 OTC 41 3,70E-06 24,79 0,16
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KIAA0543 175080 OTC 38 9,15E-05 4,01 2,03
FBXO46 471664 OTC 37 1,67E-05 4,44 2,85
CD33 1917430 OTC 35 1,06E-05 4,55 3,71
TH 813654 OTC 32 8,32E-04 3,41 1,95
IMAGE:742061 742061 OTC 31 1,99E-05 4,39 2,73
IDH3B 723755 OTC 27 1,90E-05 4,41 2,27
IMAGE:359454 359454 OTC 23 1,31E-05 24,50 0,27
SST 39593 OTC 23 1,34E-03 3,26 1,81
DHRS6 364412 OTC 20 4,03E-04 23,61 0,48
IMAGE:136933 136933 OTC 19 6,25E-03 2,77 2,19
TPM2 740620 OTC 18 1,59E-05 24,45 0,30
TM7SF3 666928 OTC 14 3,58E-04 3,65 2,00
PREB 740347 OTC 5 1,29E-02 22,51 0,33
LRRIQ2 487152 OTUM 59 1,29E-04 3,92 2,01
LRRC28 26519 OTUM 53 2,04E-04 23,80 0,43
NDUFC1 796513 OTUM 53 2,65E-03 23,05 0,61
NUMBL 1855110 OTUM 53 2,94E-04 23,70 0,56
IMAGE:667527 667527 OTUM 48 2,31E-04 3,77 2,45
MAK 382002 OTUM 43 3,71E-04 3,64 2,14
PCGF4 740457 OTUM 43 3,06E-04 3,69 2,61
IFITM3 713623 OTUM 42 1,74E-02 2,40 1,63
CLGN 1049033 OTUM 40 1,52E-03 3,23 1,86
DEFB1 665086 OTUM 40 9,17E-04 3,38 2,79
IMAGE:669098 669098 OTUM 35 9,47E-04 3,37 1,85
GNAS 382791 OTUM 31 6,58E-04 3,47 2,75
PTTG1 742935 OTUM 29 7,53E-03 22,71 0,52
USP14 376462 OTUM 28 9,21E-03 22,64 0,65
SNF7DC2 730401 OTUM 25 1,36E-02 2,49 1,51
C21orf84 730814 OTUM 19 1,24E-03 3,29 2,08
TCTE3 136862 OTUM 19 2,48E-02 22,27 0,69
TH 813654 OTUM 19 3,81E-02 22,09 0,69
BAK1 235938 OTUM 16 1,12E-03 3,32 1,80
PAX6 230882 OTUM 12 1,28E-02 22,52 0,66
CDH3 359051 PTC 99 1,00E-07 9,16 3,95
DPP4 343987 PTC 98 1,00E-07 8,72 4,22
CLDN1 594279 PTC 86 1,00E-07 7,88 8,98
SEP-02 729542 PTC 83 2,60E-01 1,13 1,20
ABCC3 208097 PTC 74 1,00E-07 6,30 3,48
ECM1 301122 PTC 67 1,00E-07 8,24 6,00
TSC 745490 PTC 60 1,00E-07 7,70 4,65
QPCT 711918 PTC 57 1,00E-07 7,27 3,36
ADAMTS9 376153 PTC 48 6,40E-06 4,66 1,95
IMAGE:687667 687667 PTC 48 1,00E-07 7,10 3,74
SLPI 378813 PTC 46 1,00E-07 7,03 2,98
MATN1 1624260 PTC 43 1,00E-07 26,74 0,42
CITED1 265558 PTC 40 1,00E-07 6,84 4,88
CCND1 324079 PTC 38 1,00E-07 6,39 2,55
IMAGE:136976 136976 PTC 23 1,00E-07 6,15 2,11
PET112L 743125 PTC 20 1,00E-07 6,27 1,96
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The clinical diagnosis of thyroid tumors is subject to significant
inter- and intra-observer variations [22,23]. Since 2001, various
molecular markers for thyroid tumors have been proposed on the
basis of microarray analysis. However, none of these markers has
proved satisfactory in clinical practice, possibly because only a
small number of thyroid tumor classes were initially taken into
account. In our study, we analyzed six publicly available
microarray datasets containing 347 thyroid tissue samples and
defining as many as 12 classes of thyroid tumors. One of these
datasets, the Fontaine dataset generated by our laboratory,
comprised about half the total number of samples, including all
the differentiated follicular thyroid lesions.
With regard to the 12 classes of thyroid tumor defined, we found
thatmorethanhalfofthe104relevantandcross-validateddifferential
genes were also related to other classes, such as AT, GD, TUM,
FTAb, which were not shared by the two main datasets, i.e. the
Giordano dataset and the Fontaine dataset. This may have affected
the relevance of the signature in the classification of the follicular
pathologies, explaining the low percentage of genes common to the
two classifiers. Although the genes were selected from different sets of
classes, discrepancies of some gene profiles, for example in Cluster 5,
may be related to incomplete microarray platform compatibility or to
differential cellular environment. Interestingly, most of the genes in
Cluster 5 were involved in the process of vascular endothelial cell
expansion[24–26], whichmay representthe stromalreaction. Despite
the small number of FTC and OTC samples and the microarray
platform being restricted to 9,216 probes, our classifier was able to
validate the classification of PTC, FTC, FTA and OTC on five other
datasets (Table 3). This demonstrated the relevance of our approach
to the molecular classification of the main types of differentiated
follicular thyroid pathology.
Unsupervised analysis of the class signatures showed a separation
into three groups corresponding to benign, malignant, and
oncocytic thyroid tumors (Figure 1). The pairwise distinctions of
benign/normal and malignant tumors were consistent with
published reports, as in the case of PTC and FTA [14]. The
surprising proximity of the FTC and FTA classes in the Giordano
dataset has already been discussed [4]. This could be related to the
high homogeneity in the expression profiles of the FTC samples,
which were positive for the PAX8-PPARG rearrangement and
significantly related to the malignant profile of the PTC samples.
Thus, the clustering of the FTC- and FTA classes appears to be
related more to their heterogeneous expression profiles rather than
to their tendency to tumoralbehavior.These resultsstrongly suggest
the existence of molecular subclasses for the FTA and
FTC- samples. Interestingly, the FTC samples in the Fontaine
dataset, included in the malignant group, were negative for the
PAX8-PPARG translocation.
Symbol Clone ID Class
Cross validation
support (%)
Parametric
p-value t-value
Fold-
change
DAF 627107 PTC 16 1,00E-07 5,68 1,89
GSS 140405 PTC 7 1,00E-07 5,73 2,05
CASP3 823680 PTC 5 6,00E-07 5,20 2,08
CD9 727251 PTC 1 1,45E-05 4,47 1,57
IMAGE:687667 687667 TUM 94 1,00E-07 6,33 3,90
CREB3L2 136399 TUM 63 4,90E-06 24,73 0,48
EIF1AY 380394 TUM 55 4,02E-05 24,22 0,57
DJ462O23.2 738970 TUM 51 1,64E-05 4,44 1,63
CITED1 265558 TUM 49 1,21E-05 4,51 3,53
KLF1 208991 TUM 46 3,72E-05 24,24 0,43
SNCB 50202 TUM 45 4,68E-05 4,18 1,99
FLJ10748 726830 TUM 44 4,24E-05 4,21 1,71
ANK2 2139315 TUM 43 1,31E-03 3,27 1,68
IGFBP3 269873 TUM 39 9,68E-05 4,00 2,06
WDR1 714196 TUM 37 2,06E-04 23,80 0,65
IFNAR2 123950 TUM 36 2,56E-04 23,74 0,61
SCNN1A 741305 TUM 36 2,37E-05 24,35 0,41
TSC 745490 TUM 27 1,95E-04 3,81 2,61
NBL1 503874 TUM 24 2,47E-04 23,75 0,35
ETF1 146976 TUM 18 6,36E-04 3,48 1,63
ICOSLG 2074228 TUM 18 1,12E-03 3,32 1,55
NCB5OR 743367 TUM 15 2,03E-03 23,14 0,56
ZNF415 23939 TUM 14 4,94E-03 22,85 0,63
KLK2 1102600 TUM 9 1,39E-03 23,25 0,66
AT: autoimmune thyroiditis; FTA: macrofollicular thyroid adenoma; FTAb: microfollicular thyroid adenoma; FTC: follicular thyroid carcinoma; GD, Graves’ disease; MNG:
multinodular goiter; OTA: oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; PTC: papillary thyroid carcinoma; TUM: tumor of uncertain malignancy; and
OTUM:, oncocytic tumor of uncertain malignancy.
doi:10.1371/journal.pone.0007632.t003
Table 3. Cont.
Micrarray and Thyroid Lesions
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7632Although the histologic diagnosis of oncocytic follicular tumors
presents few problems, the two latest WHO classifications have
debated whether these tumors should be considered as an
independent class of tumors or as a variant of follicular tumors.
This question is still relevant in view of the recent results of
miRNA profiling that clearly revealed the segregation of oncocytic
tumors from other conventional follicular tumors [27]. According
to their specific gene-expression profiles as well as their mutational
status for RAS and PAX8-PPARc genes [7], oncocytic tumors
should be considered as distinct from the other follicular tumors.
The role of the ‘‘oncocytic group’’ signature in the appropriate
classification of benign and malignant tumors is debatable.
Considering the mitochondrial richness of follicular thyroid
tumors, this signature may highlight the metabolic changes during
tumorigenesis. Little is known about the etiology of oncocytomas
but their signature is composed of numerous mitochondrial and
metabolic genes, and the role played by these genes in tumor
aggressivity has not yet been established [7,20]. Interestingly, we
found that microfollicular adenomas (FTAb) were related by their
molecular profiles to oncocytic adenomas as well as to carcinomas.
Relationships between thyroid metabolism and microfollicular
lesions have been explored [28], but never in the context of
mitochondrial functions. However, in a recent study, the galectin-
3 profile associated with FTAb was reported to be related to its
role in the regulation of mitochondrial stability [29]. Galectin-3
has been also involved in thyroid tumorigenesis through its anti-
apoptotic activity [30]. Thus, the malignant potential of FTAb is
still under discussion [31].
Evaluation of the performance of the classifiers used showed
that poor performance was associated with the FTA subclasses in
Figure 2. Class prediction of the samples. Panel A shows the mean positive accuracy of classifiers during intra-dataset cross-validations for the
two main datasets, i.e. the Fontaine dataset and the Giordano dataset. Each classifier is composed of 20 genes selected by the Greedy Pairs algorithm
and using Diagonal Linear Discriminant Analysis for training and prediction. Some classifiers were trained with samples from the selected class and
the normal tissue, i.e. with binary training (black bars). Other classifiers were trained with all the samples of the dataset, i.e. with complete training
(gray bars). Panel B shows the class prediction of new samples by binary-trained classifiers in the two datasets. All the new samples come from the
same dataset and should have been predicted as negative. The negative predictive value which was deduced from binary training (black bars) is
compared to observations on the new samples (gray bars). WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA: macrofollicular thyroid
adenoma; FTAb: microfollicular thyroid adenoma; MNG, multinodular goiter; FTC: follicular thyroid carcinoma (FTC+: with Pax8/PPARc translocation;
FTC-: without Pax8/PPARc translocation); OTA: oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; TUM: tumor of uncertain malignancy;
OTUM: oncocytic tumor of uncertain malignancy; GD, Graves’ disease; and AT, autoimmune thyroı ¨ditis.
doi:10.1371/journal.pone.0007632.g002
Table 4. Inter-dataset cross-validations. Positive accuracies of
the classifiers defined by the Fontaine dataset in five other
datasets.
DATASET PTC FTC FTA OTC OTA
Giordano et al. 2006 0.93 0.40 0.48 0.64 0.59
Weber et al. 2005 - 0.77 0.96 0.72 -
Jarzab et al. 2005 1.00 - - - -
Reyes et al. 2006 1.00 - - - -
He et al. 2005 1.00 - - - -
FTA: macrofollicular thyroid adenoma; FTC: follicular thyroid carcinoma; OTA:
oncocytic thyroid adenoma; OTC: oncocytic thyroid carcinoma; and PTC:
papillary thyroid carcinoma.
doi:10.1371/journal.pone.0007632.t004
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FTA samples may have influenced the performance of the
classifiers in discriminating true FTA from hyperfunctioning
nodules. Only 12% of macrofollicular adenomas presented
mutations in the TSH receptor or GNAS genes. These results
correlated on microarray analysis with the expression profile of
several genes previously associated with the hyperfunctional status
of nodules [32]. Even though our FTA group represents a mix of
adenomas in terms of functional status, the signature of follicular
adenoma defined by our classifier are involved in other processes
than iodine uptake and thyroid hormone secretion. As the selected
genes are mainly associated to cell metabolism (CABIN1,
CAMK2A, DAP, PDK4), signal transduction (ASGR1, PLXNB2,
TBC1, PLCG1) and cell adhesion (COL18A1), we believe that the
FTA signature we propose can discriminate true FTA from other
follicular thyroid tumors. The relevance of constructing subclasses
of follicular adenomas was tested on six cross-validated markers
and six specific markers from our own analysis (Figure 4). Five
specific markers enabled us to segregate micro- and macro-
follicular adenomas from oncocytic adenomas and minimally
invasive follicular carcinomas, while only one of the six cross-
validated markers showed the same performance. Distinguishing
between subclasses of adenoma allowed the identification of
relevant molecular markers of follicular adenomas. These markers
had never been differentially selected during previous microarray
analyses of thyroid tumors. However, three of the markers
(ADAMTS2, ALDH1A3 and CABIN1) had been proposed as
prognostic markers for the recurrence of epithelial tumors
[33–35].
The observation of six protein profiles highlights the difficulty of
proposing immunomarkers for clinical practice. However, some
markers may be relevant for the classification of differentiated
follicular pathologies (FTA, FTC, PTC, OTA and OTC). It has
been suggested that APOD, which has a specific protein profile for
FTC and PTC, may modify the proliferative activity of cancer
cells [36]. The differential expression of the folding protein
calmegin (CLGN) with FTA and FTC samples may be associated
with a difference in the abundance of the protein, as recently
described in thyroid tumors [37]. Furthermore, increasing the
number of thyroid tumor classes has revealed new aspects of some
of the markers. Thus, TIMP1 and CRABP1 were not selected by
our classifier but figured in the intersecting differential gene lists.
Our data clearly questioned the relevance of TIMP1 as a marker
of thyroid cancer. Since high protein levels were observed in the
AT and PTC classes, TIMP1 expression may be more closely
related to the frequently described lymphocytic infiltration in PTC
[38]. Quantitative RT-PCR analysis on new follicular samples
confirmed the upregulation of CRABP1 expression in all the
adenomas as compared to follicular carcinomas. Underexpression
of CRABP1 mRNA was relevant in distinguishing the FTC as well
as PTC classes, as reported previously [39,40]. However, our
results differed at the protein level compared to a study on cold
thyroid nodules where both the expression of CRABP1 mRNA
and the protein were downregulated compared to normal
Figure 3. Hierarchical clustering of cross-validated differential genes. The heatmap shows gene-expression levels in the Fontaine dataset
for the tissue classes common to the Giordano dataset (104 genes). Functional enrichments are shown for five identified gene clusters on the right,
followed by p-values and the genes involved. The black text represents Level 3 Gene Ontology terms; the blue text represents canonical Ingenuity
pathways. Gene profiles of the differential genes reflect the class similarities observed. WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA:
macrofollicular thyroid adenoma; FTC: follicular thyroid carcinoma; OTA: oncocytic thyroid adenoma; and OTC: oncocytic thyroid carcinoma.
doi:10.1371/journal.pone.0007632.g003
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Cluster Symbol UGCluster Clone ID P-value P-value
(Fontaine et al. 2008) (Giordano et al. 2006)
1 CASP10 Hs.5353 241481 1,00E-07 1,00E-07
1 CLGN Hs.86368 1049033 1,00E-07 1,00E-07
1 DEFB1 Hs.32949 665086 1,00E-07 1,00
E-07
1 NTRK2 Hs.494312 2048801 1,00E-07 1,00
E-07
1 SDHA Hs.440475 40304 1,00E-07 1,00
E-07
1 HSPC159 Hs.372208 365045 1,00E-07 3,00
E-07
1 ALDH1A3 Hs.459538 486189 1,00E-07 8,00
E-07
1 PLCG2 Hs.413111 201467 1,00E-07 9,00
E-07
1 ARVCF Hs.370408 40633 1,00E-07 1,50
E-06
1 ELK4 Hs.497520 236155 1,00E-07 1,50
E-06
1 DCI Hs.403436 667892 1,00E-07 1,70
E-06
1 DIO1 Hs.251415 296702 1,00E-07 3,50
E-06
1 CKS2 Hs.83758 725454 2,00E-07 9,00
E-07
1 ID1 Hs.504609 1087348 2,00E-07 3,90
E-06
1 MRPS11 Hs.111286 471574 4,00E-07 1,00
E-07
1 ST6GALNAC2 Hs.592105 823590 6,00E-07 8,00
E-07
1 GFPT2 Hs.696497 485085 9,00E-07 1,00
E-07
1 PITPNC1 Hs.591185 364436 9,00E-07 2,00
E-07
1 HRK Hs.87247 767779 1,00E-06 1,00
E-07
1 MAPRE2 Hs.532824 383868 1,20E-06 1,00
E-07
1 DOK5 Hs.656582 25664 1,30E-06 1,00
E-07
1 RPS6KA5 Hs.510225 258966 1,40E-06 1,00
E-07
1 DCXR Hs.9857 724596 3,00E-06 1,00
E-07
1 ODAM Hs.143811 364706 3,30E-06 1,00
E-07
1 KLK2 Hs.515560 1102600 5,00E-06 1,30
E-06
1 F5 Hs.30054 433155 6,60E-06 1,00
E-07
1 MFAP3L Hs.593942 726821 7,60E-06 1,00
E-07
1 GALNT7 Hs.548088 381854 1,10E-05 1,00
E-07
2 AHNAK Hs.502756 238840 1,00E-07 1,00
E-07
2 APOD Hs.522555 838611 1,00E-07 1,00
E-07
2 CAMK2N1 Hs.197922 173820 1,00E-07 1,00
E-07
2 CFD Hs.155597 666128 1,00E-07 1,00
E-07
2 FCGBP Hs.111732 154172 1,00E-07 1,00
E-07
2 FOXO1 Hs.370666 151247 1,00E-07 1,00
E-07
2 GLT8D2 Hs.631650 365271 1,00E-07 1,00
E-07
2 MATN2 Hs.189445 28584 1,00E-07 1,00
E-07
2 PRUNE Hs.78524 364324 1,00E-07 1,00
E-07
2 SLC4A4 Hs.5462 787938 1,00E-07 1,00
E-07
2 PAX8 Hs.469728 545475 1,00E-07 3,00
E-07
2 HSD17B6 Hs.524513 471641 1,00E-07 1,30
E-06
2 HBB Hs.523443 469549 1,00E-07 2,60
E-06
2 APOE Hs.654439 1870594 1,00E-07 3,70
E-06
2 CRABP1 Hs.346950 739193 1,00E-07 4,20
E-06
2 ZNF76 Hs.388024 745003 1,00E-07 4,70
E-06
2 C20orf19 Hs.187635 366032 1,00E-07 5,00
E-06
2 DEPDC6 Hs.112981 669318 2,00E-07 1,00
E-07
2 CDH16 Hs.513660 726763 5,00E-07 1,00
E-07
2 HBA2 Hs.654744 469647 6,00E-07 1,80
E-06
2 SASH1 Hs.193133 31120 1,40E-06 1,00
E-07
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2 HEXIM1 Hs.15299 342551 2,20E-06 1,00
E-07
2 GJA1 Hs.74471 839101 2,30E-06 1,40
E-06
2 TIMP3 Hs.644633 501476 4,30E-06 4,80
E-06
2 IL11RA Hs.591088 1101773 5,50E-06 7,00
E-07
3 APLP2 Hs.695920 549054 1,00E-07 1,00
E-07
3 DCN Hs.694789 666410 1,00E-07 1,00
E-07
3 FRMD4B Hs.371681 669564 1,00E-07 1,00
E-07
3 HMGB2 Hs.434953 884365 1,00E-07 1,00
E-07
3 IGF2BP2 Hs.35354 743774 1,00E-07 1,00
E-07
3 LOC400451 Hs.27373 667174 1,00E-07 1,00
E-07
3 NPAL3 Hs.523442 738970 1,00E-07 1,00
E-07
3 PBXIP1 Hs.505806 366042 1,00E-07 1,00
E-07
3 PDGFRL Hs.458573 139242 1,00E-07 1,00
E-07
3 PDLIM1 Hs.368525 135689 1,00E-07 1,00
E-07
3 PSAT1 Hs.494261 366388 1,00E-07 1,00
E-07
3 SF3B1 Hs.632554 739247 1,00E-07 1,00
E-07
3 TIAM1 Hs.517228 23612 1,00E-07 1,00
E-07
3 TSHR Hs.160411 565317 1,00E-07 1,00
E-07
3 FAM111A Hs.150651 137454 1,00E-07 4,00
E-07
3 CA11 Hs.428446 282587 3,00E-07 1,00
E-07
3 HNRPA3 Hs.516539 365349 5,00E-07 2,60
E-06
4 ABCC3 Hs.463421 208097 1,00E-07 1,00
E-07
4 CDH3 Hs.461074 359051 1,00E-07 1,00
E-07
4 CITED1 Hs.40403 265558 1,00E-07 1,00
E-07
4 CLDN1 Hs.439060 594279 1,00E-07 1,00
E-07
4 DPP4 Hs.368912 343987 1,00E-07 1,00
E-07
4 DUSP5 Hs.2128 33285 1,00E-07 1,00
E-07
4 NOTCH2 Hs.487360 1641901 1,00E-07 1,00
E-07
4 QPCT Hs.79033 711918 1,00E-07 1,00
E-07
4 S100A4 Hs.654444 868577 1,00E-07 1,00
E-07
4 SCEL Hs.534699 668239 1,00E-07 1,00
E-07
4 SLPI Hs.517070 378813 1,00E-07 1,00
E-07
4 TESC Hs.525709 745490 1,00E-07 1,00
E-07
4 TIMP1 Hs.522632 162246 1,00E-07 1,00
E-07
4 MGAT3 Hs.276808 731060 1,00E-07 8,00
E-07
4 MDK Hs.82045 309009 2,00E-07 1,00
E-07
4 BID Hs.591054 128065 6,00E-07 1,00
E-07
4 NRIP1 Hs.155017 38775 6,00E-07 1,00
E-07
4 COL8A2 Hs.353001 486204 1,00E-06 1,00
E-07
4 MRC2 Hs.7835 235882 1,60E-06 9,00
E-07
4 STAT1 Hs.699271 110101 2,10E-06 1,00
E-07
4 ARMCX3 Hs.592225 251452 2,40E-06 1,00
E-07
4 LAMB3 Hs.497636 1103402 9,90E-06 1,00
E-07
4 CD55 Hs.527653 627107 1,30E-05 1,00
E-07
5 DUS4L Hs.97627 726904 1,00E-07 1,00
E-07
5 ESRRG Hs.444225 44064 1,00E-07 1,00
E-07
5 ISG20 Hs.459265 740604 1,00E-07 1,00
E-07
5 ROR2 Hs.644776 1089025 1,00E-07 1,00
E-07
5 S100A11 Hs.417004 143957 1,00E-07 1,00
E-07
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functioning nodules, we postulate that this difference in protein
level may be due to the histological class studied, macrofollicular
adenomas in the Fontaine dataset, as opposed to the mix of
follicular adenomas and adenomatous nodules in the other study.
While all these markers can be used to complement current
markers [42], the exploration of a large panel of protein markers
to improve the differential diagnosis may rapidly become more
cumbersome and less relevant than the study of the expression
profile of selected genes, especially in the case of suspicious
nodular thyroid lesions.
In conclusion, diagnostic tools defined on the basis of thyroid
microarraydataaremorerelevant when many samples andtissue
classes are used, especially with the inclusion of oncocytic tumors.
Our study has revealed additional potentially useful gene and
protein markers allowing the classification of several thyroid
pathologies. However, to identify early events of transformation,
these markers should be viewed in the context of the biological
processes in which they participate. We therefore believe that
dedicated gene-expression profiling offers the most powerful
method of identifying gene groups that correlate to nodular
growth, thyroid dedifferentiation or malignancy, taking into
account the potential contamination by other cell types such as
activated lymphocytes. In this context, the molecular classifica-
tion of microfollicular adenomas on fine needle aspiration
biopsies should have a direct impact in the management of such
tumors.
Materials and Methods
Samples and microarray datasets
We analyzed gene-expression data from six microarray
datasets containing up to 12 classes of differentiated thyroid
pathologies and normal thyroid tissue. The FTA samples were
divided into two subclasses according to their follicular
architecture, FTA (macrofollicular) and FTAb (microfollicu-
lar). The dominant nodule within the multinodular goiter
(MNG) was investigated to explore the incidence of genetic or
environmental events on the molecular signature of the class of
follicular adenoma. When possible, the FTC class was also
divided into two subclasses, FTC+ and FTC-, defined
respectively by the presence or absence of the PAX8/PPARc
translocation in the samples. Atypical (TUM) and oncocytic
features (OT) were individualized on criteria specified
elsewhere [15,20]. We also explored non-tumoral lesions such
as those in Graves’ disease (GD) and autoimmune thyroiditis
(AT) to identify the immunological environment of the tumoral
samples. This study is based on the Fontaine dataset generated
by our laboratory, which comprises 12 subclasses containing a
total of 166 anonymized human thyroid tissues. The five other
datasets, particularly the Giordano dataset with 7 subclasses,
were used to cross-validate the results of the molecular
classification, the classifiers, and the functional analysis of
differential genes [5,43–45]. One dataset (Reyes et al.) has not
yet associated citation. Details of the six datasets, containing a
total of 347 samples, are summarized in Table 1.
The Fontaine and the Giordano datasets are referred as the main
datasets. All the datasets, generated by various microarray platforms
(Table 1), are publicly available. The Fontaine dataset (GSE6339), the
He dataset (GSE3467) and the Reyes dataset (GSE3678) are hosted
by the Gene Expression Omnibus (GEO) database of the U.S.
National Center for Biotechnology Information. The Weber dataset
was downloaded from European Bioinformatics Institute ArrayEx-
press database (E-MEXP-97). The two other datasets were
downloaded from the authors’ websites: the Giordano dataset
(http://dot.ped.med.umich.edu:2000/pub/PPARG/index.html) and
the Jarzab dataset (http://www.genomika.pl/thyroidcancer/
PTCCancerRes.html).
Data analysis
For the Fontaine dataset generated in our laboratory,
hierarchical clustering of the data was computed on log-
transformed, median gene-centered and normalized data as
described elsewhere [15]. Normalized data from the Giordano
and Jarzab datasets were downloaded from the authors’ websites.
For the remaining datasets, raw data were downloaded from the
GEO or Array Express databases and normalized with BRB Array
Tools v3.7.0b1 developed by Dr. Richard Simon. Since the data
originated from three different but one-color platforms, global
normalization to the median was used to center the gene-
expression values in each array. Genes showing minimal variation
across the set of arrays were excluded from the analysis (log-
intensity variation P-value.0.15). Hierarchical clustering was
done on centered genes by using the centered correlation distance
and an average linkage method. Robustness and discrepancy
indices were computed from 10,000 data perturbations.
For the two largest datasets [5,15], we identified genes that were
differentially expressed among the classes by using a multivariate
10,000-permutation test, to provide 95% confidence that the
number of false discoveries did not exceed 1. Although F-statistics
were used for each gene, the multivariate permutation test is non-
parametric and does not require the assumption of Gaussian
distributions. Functional enrichments in gene clusters were defined
at 5% risk for Level 3 Gene Ontology terms by Fatigo tools
(adjusted P-values, www.fatigo.bioinfo.cipf.es [46]) as compared to
the whole genome, and for canonical pathways by Ingenuity
Pathway Analysis tools as compared to the Ingenuity Pathways
Knowledge database (www.ingenuity.com).
Cluster Symbol UGCluster Clone ID P-value P-value
(Fontaine et al. 2008) (Giordano et al. 2006)
5 SEMA4D Hs.655281 210587 1,00E-07 1,00
E-07
5 CD58 Hs.34341 2103105 1,00E-07 2,00
E-07
5 IRF9 Hs.1706 724588 1,10E-06 3,20
E-06
5 MCOLN1 Hs.631858 726156 2,00E-06 2,00
E-07
5 ITGB7 Hs.654470 1337232 1,09E-05 2,90
E-06
doi:10.1371/journal.pone.0007632.t005
Table 5. Cont.
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PLoS ONE | www.plosone.org 14 October 2009 | Volume 4 | Issue 10 | e7632Figure 4. Gene expression of selected markers. Differential expression of 12 genes measured by real-time quantitative RT-PCR on 32 new
follicular thyroid tumors (8 FTA, 8 FTAb, 8 OTA and 8 FTC). The upper and the lower limits of each box represent the upper and the lower quartiles,
respectively. The bold lines represent medians. The expression of ADAMTS2, CABIN1, ADLH1A3, USP13, NR2F2, KRTHB5, CASP10, CDH16, CLGN,
CRABP1, HMGB2 and ALPL2 genes was referred to the b-globin expression level. Significances of differential expression between the classes were
assessed by t-tests and those over the classes by F-tests. FTA: macrofollicular thyroid adenoma; FTAb: microfollicular thyroid adenoma; FTC: follicular
thyroid carcinoma; and OTA: oncocytic thyroid adenoma.
doi:10.1371/journal.pone.0007632.g004
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trained either versus t h ew i l dt y p ec l a s s( b i n a r yt r a i n i n g )o rt h e
entire dataset (complete training). Twenty genes were selected
by the Greedy Pairs algorithm, and Diagonal Linear Discrim-
inant Analysis (DLDA) was used for training and sample [47].
Intra- and inter-dataset cross-validations were done by the
0.632+ method and DLDA respectively [48]. Since the
classical accuracy coefficient is biased in large datasets
containing unbalanced class sizes, we preferred to use the
positive accuracy coefficient defined as the geometric mean of
the sensitivity (i.e. the proportion of true positives in the
samples belonging to the targeted class in the entire datasets)
and the positive predictive value (i.e. the proportion of true
positives in the samples belonging to the targeted class) [49].
Quantitative RT-PCR analysis
An independent set of 32 follicular tumors, comprising 8
minimally invasive FTC and 24 follicular adenoma (8 OTA, 8
FTA and 8 FTAb), were subjected to real-time quantitative RT-
PCR to test the relevance of several selected markers. The
anonymized samples were obtained from the Department of
Pathology of the University Hospital of Angers, France.
Total RNA was isolated using the TRIzol reagent (Invitro-
gen, Paisley, UK). RNA integrity was determined using a Bio-
Analyzer 2100 (Agilent Technologies, Waldbronn, Germany).
Reverse transcription was performed on 1 mgo fR N Aw i t h
Advantage RT-for-PCR kit (Clontech Laboratory, Palo Alto,
CA, USA) following the manufacturer’s recommendations.
Real-time quantification was performed in a 96-well plate
using the IQ SYBR Green supermix and Chromo4 (Biorad,
Hercules, CA, USA) with the recommended protocol. Twelve
genes were explored for their expression levels: CASP10,
CDH16, CLGN, CRABP1, HMGB2, ALPL2, ADAMTS2,
CABIN1, ALDH1A3, USP13, NR2F2 and KRTHB5. Data
were normalized to the b- g l o b i ne x p r e s s i o nl e v e l .T h e
significance of differential expression between classes was
assessed by t-tests and that over the classes by F-tests. The
primer sequences used in this study are specified in Table 6.
Detection of mutations and PAX8-PPARG rearrangement
The mutational status for the TSHR, GNAS and NRAS
genes was determined for all the FTA and FTAb explored in
studies by microarray (26 FTA and 17 FTAb) and RT-PCR (8
FTA and 8 FTAb). DNA was isolated from frozen tissues
during the guanidium isothiocyanate procedure (TRIzol
Reagent, Invitrogen Life Technologies). Exon 2 of the NRAS
gene was amplified using primer sequences described else-
where[50]. Exons 9 and 10 of the TSH receptor gene, and
exons 8 and 9 of the Gs alpha gene were amplified using
primer sequences previously specified [51]. PCR were
performed on 5 ml DNA with the HotGoldstar DNA polymer-
ase (Eurogentec, Seraing, Belgium) according to the manufac-
turer’s recommendations. Amplified fragments were purified
and directly sequenced on a CEQ 8000 apparatus, using the
CEQ DTCS Quick Start Kit (Beckman Coulter, Fullerton,
CA, USA) following the manufacturer’s instructions.
The presence of the PAX8-PPARG translocation was evaluated
as described elsewhere [52], on the three FTC samples in the
microarray study and the eight FTC samples in the RT-PCR
study. Quantification, degradation and DNA contamination of
RNA were assessed using an RNA 6000 Nano Assay kit (Agilent
Technologies, Palo Alto, CA, USA). After reverse transcription,
we looked for the translocation in 5 ml cDNA, using primer
sequences previously specified [5] and the HotGoldstar DNA
polymerase (Eurogentec, Seraing, Belgium) according to the
manufacturer’s recommendations.
Figure 5. Protein expression of selected genes. The protein expression of six selected differential genes was measured on 49 new tissue
samples. These independent samples represent six tissue classes that are common to the two main datasets (WT, PTC, FTA, FTC, OTA, and OTC). The
AT class was added to compare the expression levels with a non-tumoral lesion. Seven samples were used for each class. Protein expression profiles
of APOD, CLGN, SDHA, APOE, CRABP1 and TIMP1 are shown by box-plots for the different classes of tissue. Significances of differential expression
over the classes were assessed by F-tests. P-values are shown between brackets. WT: wild type tissue; PTC: papillary thyroid carcinoma; FTA:
macrofollicular thyroid adenoma; FTC: follicular thyroid carcinoma; OTA: oncocytic thyroid adenoma; and OTC: oncocytic thyroid carcinoma.
doi:10.1371/journal.pone.0007632.g005
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Two micrograms of protein corresponding to the TRIzol
fraction of 49 independent and anonymized thyroid tissues were
spotted onto nitrocellulose membranes at room temperature, using
a Dot Blot apparatus (Biorad, Hercules, CA, USA) following the
manufacturer’s recommendations. These tissues, provided by the
Department of Pathology of the University Hospital of Angers,
differed from those used for the microarray and RT-PCR studies.
Six groups of thyroid pathologies were defined according to WHO
cytological criteria: AT, FTA, FTC, PTC, OTA and OTC and
compared to normal thyroid tissue (WT). Seven samples were
tested from each group and the assays were performed in
duplicate. Seven primary antibodies (all from Abcam, Cambridge,
UK) were used at specific dilutions: 1/750 for TIMP1, 1/1000 for
APOD, SDHA, CLGN, CRABP1 and APOE, and 1/5000 for a-
tubulin as a control. Peroxidase anti-rabbit or anti-mouse
secondary antibodies were revealed using the ECL Plus reagent
kit (ECL, Amersham, Chalfont, UK). Spots were quantified on a
GelDoc XRS apparatus using Quantity One software (Biorad) and
expressed in terms of the control value. Significances of differential
expression over the classes were assessed by F-tests.
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